alexa Cefepime: the next generation?
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Sanders CC

Abstract Share this page

Abstract Cefepime is a new aminothiazolylacetamido cephalosporin with a wider spectrum and greater potency than many currently available cephalosporins. It appears that these characteristics result from multiple properties of the molecule. In contrast to older cephalosporins, cefepime more rapidly penetrates the gram-negative cell, targets multiple essential penicillin-binding proteins, and escapes the effects of many beta-lactamases due to the enzymes' low affinity for the drug. The latter characteristic is most apparent in studies of Bush group 1 beta-lactamases. Derepression of this class of beta-lactamases has less effect on the in vitro activity of cefepime than on that of other cephalosporins. The results of clinical trials should now be carefully analyzed to determine whether these advantages carry over into the clinical arena.
This article was published in Clin Infect Dis and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords